Only a Third of Philadelphia Pharmacies Carry Life Saving Nasal Spray
Newswise — A new study from researchers at the University of Illinois at Chicago finds that only one-third of pharmacies in Philadelphia carry naloxone nasal spray, a medication used to rapidly counter the effects of opioid overdose, and that many of the pharmacies that do carry the drug require patients to have a physician’s prescription for it.
Pennsylvania has one of the highest rates of death by opioid overdose in the U.S. and was the first state to implement a statewide standing order for the drug, which is commonly known as Narcan. The law was intended to increase the availability of the potentially life-saving opioid antidote by allowing pharmacists to dispense the drug to anyone.
However, findings from this study suggest that Pennsylvania’s naloxone access law, which was enacted in 2015, is not fully implemented — putting many communities at risk.
The study, which is published in JAMA Network Open, relied on primary data collected by phone from nearly all of Philadelphia’s community pharmacies in 2017.
Senior author Dima Qato, associate professor of pharmacy systems, outcomes and policy at UIC’s College of Pharmacy, says that these findings provide evidence that despite statewide efforts to improve community access to naloxone, unnecessary barriers remain — including for people who may benefit most from the drug.
“Efforts to strengthen the implementation of naloxone access laws, including statewide standing orders, which are considered the least restrictive, are warranted,” Qato said. “Particularly for pharmacies located in communities with the highest rates of death due to opioid overdose.”
Of the 418 pharmacies included in the study, only 34.2% had naloxone nasal spray in stock. Qato and her colleagues found that the drug was more likely to be available in chain stores, compared with independent stores; it was less likely to be available in stores located in predominately minority neighborhoods, compared with predominately white neighborhoods; and, most significantly, it was less likely to be available in areas with high rates of opioid overdose deaths, or OODs, compared with areas of low OODs.
For more information about naloxone, click here.
Read the full press release.
Did you enjoy this article?
Subscribe to the PAINWeek Newsletter
and get our latest articles and more direct to your inbox